Cargando…

From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous group of clonal disorders characterized by abnormal proliferation of undifferentiated myeloid progenitors, impaired hematopoiesis, and variable response to therapy. To date, only about 30% of adult patients with AML become long-term survivors and relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurnari, Carmelo, Voso, Maria Teresa, Maciejewski, Jaroslaw P., Visconte, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072629/
https://www.ncbi.nlm.nih.gov/pubmed/32033196
http://dx.doi.org/10.3390/cancers12020357
_version_ 1783506451039256576
author Gurnari, Carmelo
Voso, Maria Teresa
Maciejewski, Jaroslaw P.
Visconte, Valeria
author_facet Gurnari, Carmelo
Voso, Maria Teresa
Maciejewski, Jaroslaw P.
Visconte, Valeria
author_sort Gurnari, Carmelo
collection PubMed
description Acute myeloid leukemia (AML) is a heterogeneous group of clonal disorders characterized by abnormal proliferation of undifferentiated myeloid progenitors, impaired hematopoiesis, and variable response to therapy. To date, only about 30% of adult patients with AML become long-term survivors and relapse and/or disease refractoriness are the major cause of treatment failure. Thus, this is an urgent unmet clinical need and new drugs are envisaged in order to ameliorate disease survival outcomes. Here, we review the latest therapeutic approaches (investigational and approved agents) for AML treatment. A specific focus will be given to molecularly targeted therapies for AML as a representation of possible agents for precision medicine. We will discuss experimental and preclinical data for FLT3, IDH1, BCL-2, Hedgehog pathway inhibitors, and epitherapy.
format Online
Article
Text
id pubmed-7072629
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70726292020-03-19 From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia Gurnari, Carmelo Voso, Maria Teresa Maciejewski, Jaroslaw P. Visconte, Valeria Cancers (Basel) Review Acute myeloid leukemia (AML) is a heterogeneous group of clonal disorders characterized by abnormal proliferation of undifferentiated myeloid progenitors, impaired hematopoiesis, and variable response to therapy. To date, only about 30% of adult patients with AML become long-term survivors and relapse and/or disease refractoriness are the major cause of treatment failure. Thus, this is an urgent unmet clinical need and new drugs are envisaged in order to ameliorate disease survival outcomes. Here, we review the latest therapeutic approaches (investigational and approved agents) for AML treatment. A specific focus will be given to molecularly targeted therapies for AML as a representation of possible agents for precision medicine. We will discuss experimental and preclinical data for FLT3, IDH1, BCL-2, Hedgehog pathway inhibitors, and epitherapy. MDPI 2020-02-04 /pmc/articles/PMC7072629/ /pubmed/32033196 http://dx.doi.org/10.3390/cancers12020357 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gurnari, Carmelo
Voso, Maria Teresa
Maciejewski, Jaroslaw P.
Visconte, Valeria
From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
title From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
title_full From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
title_fullStr From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
title_full_unstemmed From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
title_short From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
title_sort from bench to bedside and beyond: therapeutic scenario in acute myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072629/
https://www.ncbi.nlm.nih.gov/pubmed/32033196
http://dx.doi.org/10.3390/cancers12020357
work_keys_str_mv AT gurnaricarmelo frombenchtobedsideandbeyondtherapeuticscenarioinacutemyeloidleukemia
AT vosomariateresa frombenchtobedsideandbeyondtherapeuticscenarioinacutemyeloidleukemia
AT maciejewskijaroslawp frombenchtobedsideandbeyondtherapeuticscenarioinacutemyeloidleukemia
AT viscontevaleria frombenchtobedsideandbeyondtherapeuticscenarioinacutemyeloidleukemia